IXICO plc (AIM:IXI) (IXI) said it is aligning its IXI™ Platform with Medidata, a Dassault Systèmes brand, to create an integrated neuroimaging data and analysis offering that delivers a "unified user experience" for clinical trials.
The company said the technology collaboration will enable streamlined reporting of eligibility and safety criteria and allow sponsors to collect, upload, manage and receive analysis on complex neuroimaging data within a highly secure, regulatory‑compliant system; the agreement is non‑exclusive and IXICO will continue to contract directly with biopharma clients and seek other partnership opportunities.
Bram Goorden, Chief Executive Officer of IXICO, commented: "This is an exciting opportunity to power the future of neuroimaging clinical trials. This commercial agreement supports our strategy to expand the reach of our platform and analytics capabilities and serve some of the most important clinical programs and biopharma customers at scale. Medidata is a highly respected global leader in life science solutions, and we are delighted to be working with them."
Wayne Walker, Senior Vice President, Data Experience at Medidata, added: "Through this collaboration, both IXICO and Medidata can expand their impact in Central Nervous System clinical trials. Medidata's ability to deliver precise data for complex neurological conditions will elevate IXICO's proprietary platform, empowering CROs to deliver a vastly superior, unified experience to their biopharma sponsors and accelerating the critical clinical research needed to treat neurological disorders."
The company said the collaboration is expected to provide IXICO with expanded scale, opportunities for technological co‑development, market reach and an additional route to market beyond its existing commercial activities.
